美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Pharmacyclics

255.00

+0.10000.04%

成交量：29.91萬

成交額：7,627.05萬

市值：196.55億

市盈率：277.17

高：255.95

開：255.16

低：254.45

收：254.90

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Pharmacyclics

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.pharmacyclics.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Pharmacyclics的公司是一家生物製藥公司，致力於開發和銷售創新的小分子藥物用於癌症和免疫介導的疾病的治療。 Pharmacyclics的市場IMBRUVICA（ibrutinib），但有其他候選產品處於臨床開發和優化鉛的幾個臨床分子。IMBRUVICA是一個先入級，口服，每日一次治療，抑制一種稱為布魯頓的酪氨酸激酶（BTK）蛋白。 IMBRUVICA正在聯合開發和Pharmacyclics的和揚森生物技術公司及其附屬公司（揚森），強生公司的楊森製藥公司之一商品化。IMBRUVICA目前被批准用於在大約40個國家，包括美國，加拿大和歐盟範圍內的28個國家（EU）的使用。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PCYC/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PCYC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PCYC\",,,,,undefined,":{"symbol":"PCYC","market":"US","secType":"STK","nameCN":"Pharmacyclics","latestPrice":255,"timestamp":1431115200000,"preClose":254.9,"halted":0,"volume":299100,"delay":0,"floatShares":52729884,"shares":77080000,"eps":0.92,"marketStatus":"休市中","change":0.1,"latestTime":"05-08 16:00:00 EDT","open":255.16,"high":255.95,"low":254.45,"amount":76270500,"amplitude":0.005885,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.92,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":254.9,"volumeRatio":0.574287},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PCYC\",,,,,undefined,":{"symbol":"PCYC","floatShares":52729884,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.574287,"shares":77080000,"dividePrice":0,"high":255.95,"amplitude":0.005885,"preClose":254.9,"low":254.45,"week52Low":254.45,"pbRate":"--","week52High":255.95,"institutionHeld":0,"latestPrice":255,"eps":0.92,"divideRate":0,"volume":299100,"delay":0,"ttmEps":0.92,"open":255.16,"prevYearClose":255},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.pharmacyclics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Pharmacyclics的公司是一家生物製藥公司，致力於開發和銷售創新的小分子藥物用於癌症和免疫介導的疾病的治療。 Pharmacyclics的市場IMBRUVICA（ibrutinib），但有其他候選產品處於臨床開發和優化鉛的幾個臨床分子。IMBRUVICA是一個先入級，口服，每日一次治療，抑制一種稱為布魯頓的酪氨酸激酶（BTK）蛋白。 IMBRUVICA正在聯合開發和Pharmacyclics的和揚森生物技術公司及其附屬公司（揚森），強生公司的楊森製藥公司之一商品化。IMBRUVICA目前被批准用於在大約40個國家，包括美國，加拿大和歐盟範圍內的28個國家（EU）的使用。","exchange":"NASDAQ","name":"Pharmacyclics","nameEN":"Pharmacyclics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PCYC\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PCYC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2015-05-01","symbol":"PCYC","fiscalQuarterEnding":null,"expectedEps":0.05,"name":null,"time":"","type":"earning","dateTimestamp":1430452800000,"reportTimeType":"","actualEps":0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PCYC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PCYC\",market:\"US\",delay:false,,,undefined,":{}}}